Yetzugo is a long-acting HIV-1 capsid inhibitor that reduces the risk of sexually acquired HIV in adults and adolescents.

Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...

What kind of uptake can Gilead Sciences expect for its highly touted, long-acting HIV pre-exposure prophylaxis (PrEP) ...

The US Food and Drug Administration (FDA) has approved lenacapavir as a long-acting injectable drug to prevent HIV.

The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...

He affirmed that the new drug "could take the epidemic to the history books," according to Mother Jones.Yeztugo, based on the ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

The new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or ...

Yeztugo showed promising results in clinical trials. One study involving women in Africa reported 100% efficacy, with zero ...

FDA approves powerful HIV drug that nearly eliminated spread in clinical trials. ... Called Yeztugo, the highly effective drug has inspired feverish anticipation among advocates for HIV prevention.

Like other PrEP drugs, if enough of the medication is present when a person is exposed to HIV, it can prevent the virus from ...